Furosemide and the Symptom Burden: The Potential Mediating Role of Uremic Toxins in Patients with CKD.

Fiche publication

Date publication

novembre 2025

Journal

Toxins

Auteurs

Membres identifiés du Cancéropôle Est :
Dr OMOROU Abdou Yacoubou

Tous les auteurs :
Costes-Albrespic M, Liabeuf S, Larabi IA, Laville SM, Stengel B, Omorou AY, Frimat L, Alvarez JC, Massy ZA, Alencar de Pinho N, The Ckd-Rein Study Group

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41295857

Résumé

Furosemide appears to contribute to the accumulation of protein-bound uremic toxins (PBUTs) and to induce adverse drug reactions. We investigated the extent to which the association between the furosemide dose and serum PBUT concentrations mediates the relationship between the furosemide dose and the symptom burden in patients with chronic kidney disease (CKD). This cross-sectional analysis included patients with CKD stages 2 to 5 from the CKD-REIN cohort and with data on the baseline serum concentrations of the free fractions of indoxyl sulphate (IS), kynurenine (KYN), p-cresyl sulphate (PCS), and indole-3-acetic acid (IAA), as measured by liquid chromatography-tandem mass spectrometry. The symptom burden was also assessed with a modified (8-item) symptom subscale from the Kidney Disease Quality of Life-36 (e.g., muscle soreness, cramps, itchy skin, dry skin, dizziness, appetite, numbness, and nausea). We used beta regressions to model the association between the furosemide dose and the symptom burden and used structural equation models to quantify the mediating effect of PBUT on this association. Among the 2053 included patients (males: 66%, median age: 68; mean estimated glomerular filtration rate: 35 mL/min/1.73 m), those prescribed high-dose furosemide (>120 mg/day) had higher symptom burden than those not prescribed furosemide (i.e., a 5.67-point lower symptom score, 95%CI 1.41-9.93). The sum of PBUTs explained 3.78% (95%CI 0.10-18.01%) of this association. Similar results were observed for IS, KYN, and IAA, considered separately, but not for PCS, whose estimated mediation effect was nearly null. Although high-dose furosemide was associated with a greater symptom burden in patients with CKD, mediation by PBUT accumulation appeared to be minimal.